MAPT and Alzheimer disease: In AD animal models, some plant compounds and products have been shown to constrain tau hyperphosphorylation through modulating the activity of glycogen synthase kinase-3 (GSK3) or cyclin-dependent kinase-5 (CDK5), or directly through PP2A control [100].